Business Context and Reporting Period
This Form 8-K Current Report was filed by Pulse Biosciences, Inc. on September 23, 2022. The filing reports on the appointment of Kevin Danahy as Chief Executive Officer and the associated amendment to his employment agreement, effective September 20, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Kevin Danahy was appointed Chief Executive Officer, having previously served as Chief Commercial Officer since February 14, 2022.
- Compensation Amendment: An amendment to Mr. Danahy's employment agreement was executed on September 23, 2022.
- Equity Grant: Mr. Danahy was granted an option to acquire up to 450,000 shares of common stock.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business performance. It details Mr. Danahy's background, noting over 20 years of senior management experience in medical technology, including roles at Solmetex, Zimmer Biomet, Intuitive Surgical, Medtronic, and Johnson & Johnson.
Compensation Details:
- Base Salary: $400,000 annually.
- Target Bonus: Up to 100% of base salary.
- Stock Options: 450,000 shares with an exercise price equal to the closing price on September 23, 2022, vesting in four equal installments subject to continued employment.
Investor Verification Checklist
- Verify the full text of the Danahy Amendment (Exhibit 10.1) for specific vesting conditions and termination provisions.
- Confirm the closing stock price on September 23, 2022, to determine the exercise price of the 450,000 granted options.
- Review the Company's 2017 Equity Incentive Plan to understand the total pool of shares available for future grants.
- Monitor subsequent filings for any changes in the Company's strategic direction under the new CEO leadership.